Search research articles
Contact Us
Filters
Showing results (61-70 of 101) with videos related to
Page
of 11
Sort By:
Annals of Internal Medicine
|
March 1, 1983
Opportunistic infections and Kaposi's sarcoma among Haitians: evidence of a new acquired immunodeficiency state
A E Pitchenik, M A Fischl, G M Dickinson, et al.
Annals of Internal Medicine
|
January 1, 1992
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study
T C Meng, M A Fischl, A M Boota, et al.
Journal of Acquired Immune Deficiency Syndromes
|
January 1, 1988
HIV-1 inhibition by azidothymidine in a concurrently randomized placebo-controlled trail
W P Parks, E S Parks, M A Fischl, et al.
The Journal of Infectious Diseases
|
April 1, 1994
Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories
V DeGruttola, L A Beckett, R W Coombs, et al.
The New England Journal of Medicine
|
October 11, 1990
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group
M A Fischl, C B Parker, C Pettinelli, et al.
Journal of Acquired Immune Deficiency Syndromes
|
March 1, 1993
Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group
M A Fischl, S E Krown, K P O'Boyle, et al.
Annals of Internal Medicine
|
January 1, 1995
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group
M A Fischl, K Stanley, A C Collier, et al.
Antimicrobial Agents and Chemotherapy
|
December 31, 1998
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators
X J Zhou, L B Sheiner, R T D'Aquila, et al.
The Journal of Infectious Diseases
|
September 1, 1993
Tuberculosis symposium: emerging problems and promise
J J Ellner, A R Hinman, S W Dooley, et al.
Lancet (London, England)
|
January 16, 1988
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT)
R Yarchoan, C F Perno, R V Thomas, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 101) with videos related to
Sort By:
Page
of 11
Annals of Internal Medicine
|
March 1, 1983
Opportunistic infections and Kaposi's sarcoma among Haitians: evidence of a new acquired immunodeficiency state
A E Pitchenik, M A Fischl, G M Dickinson, et al.
Annals of Internal Medicine
|
January 1, 1992
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study
T C Meng, M A Fischl, A M Boota, et al.
Journal of Acquired Immune Deficiency Syndromes
|
January 1, 1988
HIV-1 inhibition by azidothymidine in a concurrently randomized placebo-controlled trail
W P Parks, E S Parks, M A Fischl, et al.
The Journal of Infectious Diseases
|
April 1, 1994
Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories
V DeGruttola, L A Beckett, R W Coombs, et al.
The New England Journal of Medicine
|
October 11, 1990
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group
M A Fischl, C B Parker, C Pettinelli, et al.
Journal of Acquired Immune Deficiency Syndromes
|
March 1, 1993
Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group
M A Fischl, S E Krown, K P O'Boyle, et al.
Annals of Internal Medicine
|
January 1, 1995
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group
M A Fischl, K Stanley, A C Collier, et al.
Antimicrobial Agents and Chemotherapy
|
December 31, 1998
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators
X J Zhou, L B Sheiner, R T D'Aquila, et al.
The Journal of Infectious Diseases
|
September 1, 1993
Tuberculosis symposium: emerging problems and promise
J J Ellner, A R Hinman, S W Dooley, et al.
Lancet (London, England)
|
January 16, 1988
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT)
R Yarchoan, C F Perno, R V Thomas, et al.
Page
of 11